David Neil Hayes
Gründer bei GeneCentric Therapeutics, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Myla Lai-Goldman | M | 66 |
GeneCentric Therapeutics, Inc.
 GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | 13 Jahre |
| Michael V. Milburn | M | - |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | 6 Jahre |
| Clay Thorp | M | 55 |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | - |
| Charles M. Perou | M | - |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | 13 Jahre |
| Myla Lai Goldman | F | - |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | 3 Jahre |
| Arnold Levine | M | 84 |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | - |
| Ellen Lubman | F | 48 |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | - |
| Bert O'Neil | M | - |
North Carolina Cancer Hospital
 North Carolina Cancer Hospital Hospital/Nursing ManagementHealth Services The North Carolina Cancer Hospital is a cancer research and treatment center located at the University of North Carolina at Chapel Hill. The American company serves patients at the N.C. Cancer Hospital. | - |
| Robert Tarran | M | - |
North Carolina Cancer Hospital
North Carolina Cancer Hospital Hospital/Nursing ManagementHealth Services The North Carolina Cancer Hospital is a cancer research and treatment center located at the University of North Carolina at Chapel Hill. The American company serves patients at the N.C. Cancer Hospital. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Walter Capone | M | 59 |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | 4 Jahre |
| Christy Marshuetz Ferguson | M | - |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | - |
| Mark R. Miglarese | M | - |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | - |
| Hawazin Faruki | M | - |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | - |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 13 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David Neil Hayes
- Persönliches Netzwerk
